Background Patients with rheumatoid arthritis (RA) usually have high rate of comorbidities. The co-morbid diseases may greatly decrease the quality of life. Pharmacological interaction between DMARD's and medicines used to comorbidity's treatment also may potentiate DMARD's unacceptable effects.
Objectives The aim of the current study was to analyze a structure of co-morbid diseases in patients with RA in Saratov region of Russia.
Methods The study involved 328 patients with RA diagnosed with ACR (1987) and EULAR/ACR 2010 criteria observed in 2011-2013 years. The group included 17,4% men and 82,6% women; mean age was 54,6±12,6 years. Anamnesis of RA mean longevity was 10,4±9,8 years. All patients receive DMARDs by 3 month or longer. The clinical examination, questioning and data from the patient's card were evaluated.
Results Comorbidities was occurred in 86,6% of patients. 57,9% persons have 2 or more comorbid disorders. The most common co-morbid conditions were cardiovascular diseases (88,6%) includes arterial hypertension (57,7%) and ischemic heart disease (30,9%). Gastrointestinal disorders occurred in 80,3% patients: chronic inflammatory diseases of stomach and duodenum - 39,8%, chronic cholecystitis –27,1%, pancreatitis –16,5%, 5,6% patients have HCV-hepatitis.
50,7% patients have osteoarthritis (OA). 71,5% patients OA firstly occurred after then RA has been diagnosed.
Diseases of endocrinous system was diagnosed in 24,6% patients: 19,7% persons have autoimmune thyreoiditis, diabetes mellitus occurred in 4,9% patients.
11,9% patients have varicose of lower extremities.
Chronic pyelonephritis occurred in 19,7% persons.
9,5% patients have respiratory disorders: chronic obstructive pulmonary disease occurred in 2,1%, bronchial asthma – in 7,4% patients.
Conclusions Comorbidities are high-frequent conditions in patients with rheumatoid arthritis. The most common comorbid disorders are arterial hypertension and osteoarthritis. Acute inflammatory gastrointestinal and uretero-vesical diseases may become barriers to the DMARD's using. Activity of co-morbid disorders makes treating RA to target difficultly.
Disclosure of Interest None declared